relapse was discovered and a new chemotherapy regimen was started using high-dose Ara-C and etoposide as induction therapy. Five months later, while on maintenance, and A 15-year-old female with pre-pre B ALL in third relapse was treated with administration of eight blood 3 weeks after having received cyclophosphamide (1 g/m 2 ) for 1 day and BCNU (100 mg/m 2 ) for 1 day, the patient bank leukocyte concentrates per day for 5 days. The total number of mononuclear cells per kilogram of relapsed in the bone marrow for the third time. The bone marrow aspirate showed 28% blasts and the CBC hemogloweight was 4.89 ؋ 10 8 . On the fifth day of infusions the patient was in complete remission (CR), asymptomatic bin 9.1 g/dl, platelets 65 000/l, leukocytes 2500/l with a differential count of 45% neutrophils, 9% monocytes, 29% and with a normal CBC. No secondary effects were found. The patient remained in CR without treatment lymphocytes, 4% eosinophils and 13% blasts. After obtaining authorization from our hospital's ethics for 10 weeks before relapsing again. The possibility of reaching a short-lived, clinically relevant response, committee we presented this experimental option to the patient who signed an informed consent. Three weeks after using blood bank leukocyte infusions, is a promising new approach for the treatment of leukemia.
The induction of a graft-versus-disease phenomenon by administration of donor leukocyte infusions 1 as a means of Results inducing remission in patients relapsing after allogeneic bone marrow transplant (allo-BMT) for chronic myelogen-A volume of 760 ml was infused. A total of 532 ϫ 10 8 ous leukemia (CML), 2,3 acute leukemias (AL) 4 and other leukocytes was administered (49.7% mononuclear cells). hematological malignancies, 5 has been reported. This The number of mononuclear cells infused per kilogram of appears to be a graft-versus-leukemia (GVL)-like effect, weight was 4.89 ϫ 10 8 (73% CD3 ϩ , 62% CD4 ϩ , 37% similar in its mechanism of action to the responses obtained CD8 ϩ , 13% CD56 ϩ ). On the fifth day of infusions the in relapsed allo-BMT patients when immunosuppressive patient was in complete remission with 1% of blasts in the therapy is withdrawn. We report a case of relapsed acute bone marrow, asymptomatic and with a normal CBC. No lymphoblastic leukemia treated with the administration of secondary effects were associated with this therapy. The blood bank leukocytes. patient remained in complete remission without treatment for 10 weeks before relapsing again and being started on intensive chemotherapy, dying 3 weeks later.
Case report
A 15-year-old female was diagnosed with pre-pre B ALL Discussion in December 1989. She was given standard high-risk ALL treatment including CNS prophylaxis for 30 months.
It has been suggested that T cells play a central role both Eleven months after treatment ended, a bone marrow in GVL as well as GVHD after allo-BMT by two different relapse was found. Chemotherapy was started again using mechanisms: (1) a leukemia-specific major histocompaa more intensive treatment, also for 30 months. Four tibility complex (MHC) reactivity mediated through CD4 ϩ months after ending chemotherapy, a new bone marrow cytotoxic T lymphocytes; 6 and (2) a MHC non-restricted effect mediated by natural killer (NK) and lymphokineactivated killer (LAK) cells which occurs early after allo- infusions as therapy for CML relapsing after allo-BMT.
133-138.
The explanation appears to be that donor T cells may recog- We believe that the rapid remission seen in our patient 
